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ABSTRACT
Increased production and accumulation of melanin are characteristics of a large 
number of skin diseases, including melasma, post-inflammatory hyperpigmentation 
and lentigo. A number of clinical agents can reduce normal or abnormal pigmentation, 
but none of these have achieved satisfactory effects. This review discusses the mecha-
nisms behind the different approaches. Tyrosinase is a pivotal enzyme in melanin syn-
thesis. The majority of whitening or lightening agents act by specifically reducing the 
activity of tyrosinase via several mechanisms: (1) prior to melanin synthesis (interfering 
with its transcription and/or glycosylation); (2) during melanin synthesis (tyrosinase 
inhibition, peroxidase inhibition and reduction of byproducts); and (3) after melanin 
synthesis (tyrosinase degradation, inhibition of melanosome transfer, acceleration of 
skin turnover). Additional melanogenesis-associated mechanisms are also discussed.
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Introduction
Melanin performs a crucial role in protecting skin against ultra-
violet light. It also determines skin color and several aspects of 
phenotypic appearance. However, abnormal melanin accu-
mulation can potentially become an aesthetic problem. Thus, 
whitening or lightening cosmetics are utilized extensively for 
the prevention and treatment of irregular hyperpigmentation. 
Compounds with hypopigmenting activity are frequently used 
in the fields of dermatology and cosmetics for these purposes.
In this review, we deal principally with agents that can 
affect the activity or amount of tyrosinase. We also discuss 
additional agents with different mechanisms of action.
Regulation of tyrosinase and related enzymes
Inhibition of tyrosinase activity
The majority of hypopigmenting agents are tyrosinase in-
hibitors, although their classification is complicated by their 
different mechanisms. Some representative examples are 
discussed below.
Hydroquinone is a well-known tyrosinase inhibitor. The 
oxidation products of hydroquinone are thought to cause 
oxidative damage to membrane lipids and proteins includ-
ing tyrosinase, as well as glutathione depletion.1 Thus, the 
use of hydroquinone in cosmetics has been banned by the 
European Committee, because of possible long-term com-
plications.2 Several other phenolic compounds have been 
identified as depigmenting agents, and act as possible alter-
native substrates for tyrosinase. The presence of a hydroxyl 
group and an electron donor group has been suggested to 
be a fundamental requirement for this activity.3
Compared with hydroquinone, arbutin, a naturally oc-
curring hydroquinone beta-D-glucopyranoside, is commonly 
utilized in the production of cosmetics, as it is known to 
exhibit hypopigmenting activity at non-toxic concentra-
tions.4 Arbutin has been demonstrated to attenuate tyrosi-
nase activity without affecting its mRNA expression, and 
inhibits 5,6-dihydroxyindole-2-carboxylic acid polymerase 
activity.5
Kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) 
is an antibiotic generated by many species of Aspergillus and 
Penicillium. Its hypopigmenting activity has been attributed 
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to its chelating ability and its nuclear factor-kappa B (NF-
κB) activation-inhibitory effects in keratinocytes.6,7
Gentisic acid and its methyl ester (2,5-dihidroxybenzoic 
acid), a natural product of Gentiana root, inhibit melanin 
synthesis in melanocytes at non-cytotoxic concentrations.8
We also screened a range of tyrosinase inhibitors. The 
effects of 4-n-butylresorcinol on melanogenesis were eval-
uated in a spontaneously immortalized mouse melanocyte 
cell line, Mel-Ab, where it was shown to effectively inhibit 
tyrosinase activity in a cell-free system, and appeared to func-
tion as an effective direct tyrosinase inhibitor (Figure 19). In 
contrast, p-coumaric acid did not directly inhibit tyrosinase 
activity, although it was able to induce hypopigmentation 
in cells. Competitive inhibition was demonstrated between 
p-coumaric acid and tyrosine. This may indicate that an al-
ternative substrate of tyrosine can be used to induce hypo-
pigmenting effects.10
Decreased tyrosinase production
The transcription of genes encoding tyrosinase and tyrosinase-
related protein-1 is under the control of the microphthalmia 
transcription factor (MITF).11 MITF belongs to the basic helix-
loop-helix-zip family of transcription factors, and is crucial for 
both melanocyte proliferation and melanogenesis. Mutations 
in human MITF result in hypopigmentation and deafness in 
type 2A Waardenburg syndrome. As MITF is regulated by 
the Wnt signaling pathway, the p38 signaling pathway and 
the MAP kinase pathway as well as by cAMP, any agents that 
regulate these signaling pathways also have the potential to 
affect MITF and melanogenesis.
We have been searching for a signaling regulator that might 
also function as a hypopigmenting agent. For example, sus-
tained extracellular signal-regulated kinase (ERK) activation 
by sphingosine-1-phosphate (S1P) can result in MITF phos-
phorylation and degradation, which are in turn responsible for 
reduced melanin synthesis (Figure 2).12 Transforming growth 
factor (TGF)-β1 also plays an inhibitory role in pigment for-
mation. We found that TGF-β1 induced a significant delay 
in ERK activation and ERK-induced MITF downregulation, 
which could contribute to hypopigmentation.13 We also 
found that lysophosphatidic acid and C2 ceramides were 
capable of inducing MITF degradation or blocking MITF 
expression, respectively, mediated by an initial effect on 
AKT/protein kinase B or ERK.14–16 Additional evidence re-
garding the involvement of the ERK pathway in melanogenesis 
was recently uncovered, using another signaling-lipid me-
diator, sphingosylphosphorylcholine.17 This agent may in-
hibit melanogenesis via transcriptional regulation of the 
tyrosinase gene.
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Figure 1 Hypopigmenting effects of 4-n-butylresorcinol in Mel-Ab cells (modified from reference 9 with permission).
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combined with hinokitiol, which reduces MITF expression. 
Thus, the combination of two agents with different mecha-
nisms may be another useful strategy for increasing the ef-
ficacy of these agents.9
Modification of tyrosinase proteins
Tyrosinase is a copper-containing transmembrane glyco-
protein and the rate-limiting enzyme in mammalian mela-
nogenesis. Mutations at glycosylation sites have thus been 
implicated in oculocutaneous albinism in humans, char-
acterized by inactive tyrosinase and the total absence of 
pigmentation.24,25
Glucosamine or tunicamycin, which are specific inhibitors 
of lipid carrier-dependent glycosylation, have been shown 
to induce marked hypopigmentation, coupled with ultra-
structural alterations.26 Additionally, calcium D-pantetheine-
S-sulfonate, probably generated via the alteration of tyrosinase 
and TRP-1 glycosylation, exerts an inhibitory effect on mela-
nogenic enzymes, without affecting their expression, and 
causes reversible hypopigmentation in normal human 
melanocytes.27
Regulation of melanosome formation
Melanosomes are specialized subcellular organelles in which 
melanin is synthesized and deposited. Electron microscopic, 
cytochemical, genetic and biochemical evidence all sup-
port the notion that melanosomes are specialized lysosomes. 
The relationship between melanosomes and lysosomes has 
important implications for the chemistry of melanization 
and the potential pharmacologic manipulation of the process. 
Thus, melanosome formation is a crucial step in the process 
of melanization.
Interference with melanosome maturation
The addition of TGF-β1 to melanocytes yielded significantly 
more stage III melanosomes, even when the cells were 
treated concomitantly with α-melanocyte-stimulating hor-
mone to increase the production of fully melanized stage IV 
melanosomes.28 It has also been reported that sustained 
ERK activation by S1P can result in hypopigmentation.12 
Increased tyrosinase degradation
Several studies18–21 have reported on the hypopigmenting 
effects of fatty acids on melanogenesis. These effects are quite 
complex, as unsaturated linoleic acids reduce tyrosinase 
activity, while saturated palmitic or stearic acids increase it. 
Topical application of linolenic, linoleic and oleic acids (in 
decreasing order of efficiency) produced a bleaching effect on 
guinea pig skin after stimulation with UV light.18 The number 
of melanosomes and the level of tyrosinase mRNA did not 
appear to be influenced, suggesting that the hypopigmenting 
effects associated with linoleic acid were probably attribut-
able to a reduction in the amount of tyrosinase due to the 
stimulation of tyrosinase ubiquitination and proteasomal 
degradation.19,20 As an unsaturated fatty acid, phospholipase 
D2 also reduces melanogenesis via the same mechanism, i.e. 
ubiquitin-mediated degradation of tyrosinase.21 The above 
compounds provide examples of agents that suppress melano-
genesis via the increased degradation of tyrosinase proteins.
Multifunctional hypopigmenting agent or 
combinations of agents with different 
mechanisms of action
Terrein, a bioactive fungal metabolite isolated from a 
Penicillium species, has recently been reported to reduce 
melanin synthesis by reducing tyrosinase production via 
ERK activation, followed by the downregulation of MITF.22 
Interestingly, terrein also reduced melanogenesis via ubiq-
uitin-dependent proteasomal degradation, as well as via 
decreased expression of its mRNA.23 Terrein is therefore an 
example of a hypopigmenting agent that inhibits melanogen-
esis by dual actions, including the downregulation of tran-
scription and the upregulation of degradation (Figure 3).
In contrast to multifunctional terrein, the combined use 
of two agents with different mechanisms of action can pro-
duce additive effects. As described above, 4-n-butylresorcinol 
failed to induce ERK or Akt activation, or MITF degradation. 
It also had no effect on cAMP response-element binding pro-
tein phosphorylation, which stimulates MITF expression. 
However, 4-n-butylresorcinol showed an additive effect when 
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Figure 2 Extracellular signal-regulated kinase (p-ERK1) activation 
and microphthalmia transcription factor (MITF) degradation after sphin-
gosine-1-phosphate treatment.
Production Degradation
Tyrosinase
Figure 3 Mechanism of action of terrein (multifunctional tyrosinase 
inhibitor).
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Other mechanisms
Diverse antioxidants and various mechanisms
Compounds with antioxidant properties exert hypopigment-
ing effects by interacting with copper at the active site of 
tyrosinase, or with o-quinones, thus avoiding the oxidative 
polymerization of melanin intermediates. Moreover, anti-
oxidant agents inhibit the signaling process, enabling the 
stimulation of epidermal melanogenesis by scavenging reac-
tive oxygen species generated in the skin after UV exposure.37
Ascorbic acid can also interfere with the different steps of 
melanization by interacting with copper ions at the active 
site of tyrosinase, reducing dopaquinone, and by blocking the 
oxidation of 5,6-dihydroxyindole-2-carboxylic acid.38,39
α-Tocopherol (α-Toc) derivatives inhibit tyrosinase and 
melanogenesis in epidermal melanocytes. The antioxidant 
properties of α-Toc, which interfere with the lipid peroxida-
tion of membranes and increases intracellular glutathione 
content, might explain its hypopigmentation effect.40 An al-
ternative compound is α-Toc ferulate (α-Toc-F), a derivative 
of α-Toc stabilized by linkage by an ester bond to ferulic 
acid. α-Toc-F also inhibits melanin synthesis in normal 
human melanocytes, without interfering with the tyrosinase 
pathway.40
6-Hydroxy-3,4-dihydrocoumarins are another set of 
novel antioxidants with α-Toc-like chemical structures that 
have recently been reported to exert anti-melanogenic effects 
in cultured normal human melanocytes at non-cytotoxic con-
centrations, without interfering with tyrosinase activity.41 
These agents might act via acceleration of glutathione syn-
thesis and inhibition of tyrosinase transfer.42
Thioctic acid (α-lipoic acid), a disulfide derivative of oc-
tanoic acid, exerts several biological effects. It has been 
reported to prevent UV-induced oxidative damage, princi-
pally via the down-modulation of NF-κB activation. Addi-
tionally, it is known to inhibit tyrosinase activity, probably 
by chelating its copper ions.43
Inhibitors of inflammation-induced melanogenic 
response
Pro-inflammatory mediators, such as interleukin-1α and 
endothelin 1 (ET-1), are generated by keratinocytes after 
exposure to inflammatory stimuli or UV exposure, and are 
capable of stimulating melanogenesis. Anti-inflammatory 
compounds might therefore prove useful for the prevention 
or treatment of post-inflammatory hyperpigmentation.
ET-1 exerts unique and powerful stimulatory effects on 
both DNA synthesis and melanization in human melano-
cytes. Topical application of Matricaria chamomilla extract 
inhibited UVB-induced pigmentation by avoiding ET-1-
induced DNA synthesis but not interleukin-α-induced ET-1 
production and tyrosinase activation.44
Interestingly, a decreased number of pigmented melanosomes 
was detected in S1P-treated melanocytes (unpublished data). 
Moreover, S1P-treated cells produced undifferentiated early-
stage melanosomes, whereas the control cells produced 
melanosomes with internal fibrils and dense pigmentation. 
These findings suggest that skin pigmentation might repre-
sent another strategy for regulating melanosome formation. 
However, no currently available agents use this mechanism 
to achieve hypopigmentation.
Peroxidase inhibitors
The involvement of peroxidase in the polymerization of 
melanogenic intermediates is suggested by the high degree 
of efficiency of peroxidase in the oxidation of 5,6-dihydroxy-
indole, a process that generates hydrogen peroxide (H2O2) 
as a by-product.29 The inhibition of peroxidase has been 
shown to cause hypopigmentation by reducing the polym-
erization rate of eumelanin in different experimental models.30 
Methimazole is an antithyroid agent belonging to the thion-
amide group, which inhibits both mushroom tyrosinase and 
peroxidase. This agent induces a mild to moderate inhibi-
tion of melanization, and causes morphologic changes in 
melanocytes in animal models.31
Interference with melanosome transfer
Melanosome formation is a crucial step in the melanization 
process, but the melanosomes must also be transferred from 
melanocytes to keratinocytes. A decrease in melanosome 
transfer can therefore induce a skin-lightening effect. The 
inhibition of serine protease has been shown to result in 
impaired activation of protease-activated receptor 2 in ker-
atinocytes, resulting in the accumulation of melanosomes 
within melanocytes.32 Inhibition of this receptor therefore 
blocks melanosome transfer between these cells, thus also 
blocking the dispersion of pigment to keratinocytes.33 This 
suggests a potentially novel mechanism for the regulation 
of pigmentation, mediated by the inhibition of the keratino-
cyte receptor, protease-activated receptor 2. However, a pre-
viously tested unique inhibitor (RWJ-50353) has not been 
well characterized as a hypopigmenting agent. Additionally, 
centaureidine, a flavonoid glucoside isolated from yarrow, 
reduces dendritic growth and the transfer of melanosomes 
to keratinocytes.34 Moreover, niacinamide (vitamin B3) was 
also shown to inhibit melanosome transfer to keratinocytes, 
both in vitro and in vivo. However, the mechanism under-
lying this activity remains to be elucidated.35
It has also been demonstrated in an in vitro model that 
glycosylated residues on melanocyte and keratinocyte 
membranes are critical for receptor-mediated endocytosis 
and thus for facilitating melanosome transfer. Lectins and 
neoglycoproteins have also been shown to inhibit melano-
some transfer.36
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Topical corticosteroids are representative anti-inflammatory 
agents. They have been included in several clinical trials for 
the treatment of melasma, and have also been used in at-
tempts to reduce the irritation induced by hypopigmenting 
agents.45 They may act by the suppression of cytokines via the 
inhibition of NF-kB activation.
Glabridin, the principal component of the hydrophobic 
fraction of licorice extracts, reduced tyrosinase activity in B16 
melanoma cells without affecting DNA synthesis, and in-
hibited UVB-induced skin pigmentation and erythema in 
guinea pigs.46 Its observed ability to inhibit cyclooxygenase 
activity and superoxide anion production suggests that its 
anti-inflammatory effect involves interference with the ara-
chidonic acid cascade, and that protection against oxida-
tive stress performs a key role in modulating melanogenesis.
Other signal regulators
The skin on the palms of the hands and the soles of the feet is 
less pigmented than the rest of the body skin. This is caused 
by the preferential expression of transcription factors by fi-
broblasts in the underlying dermis. Some investigators have 
found that the protein product of the gene dickkopf1 (DKK1) 
is a negative regulator of the Wnt signaling pathway, which 
decreases the levels of MITF, and therefore inhibits melano-
cyte growth and pigment production.47 Similarly, calpain 
inhibitors have been shown to cause marked reductions in 
both tyrosinase and its mRNA levels in B16 cells. Thus, treat-
ment methods based on the specific stimulation of DKK1 or 
the inhibition of calpain represent potentially viable new 
approaches to the treatment of hypopigmentation.48
Conclusions
Although the knowledge of melanocyte biology has made 
remarkable progress, the pathogenic mechanisms underlying 
acquired hyperpigmentation have yet to be completely elu-
cidated. New mechanisms need to be explored to fully un-
derstand the biological basis of pigmentation, and to identify 
new and effective signal regulators. The dermal microenvi-
ronment has also been reported to influence epidermal pig-
mentation via dermal degeneration or vascular dilatation. 
These findings suggest that the environmental regulation of 
melanogenesis is a complex process. Different hypopig-
menting agents have been discussed on the basis of a review 
of the literature, and on the authors’ clinical and research 
experiences.
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